Patrick Faloon, a member of the Broad Institute’s Chemical Biology Program, oversees the high-throughput screening (HTS) automation group. Along with his colleagues, Faloon executes projects to find small-molecule probes – chemical compounds, many of which have been created by Broad researchers – with specific and potent activity against a biological pathway or disease mechanism. Such projects involve developing assays (laboratory procedures), optimizing assays for automation, screening a compound library that contains over 360,000 small molecules, and performing a series of steps to characterize each small-molecule probe. Each project involves a coordinated team of engineers, medicinal chemists, and external assay providers. Faloon works with colleagues from within the Broad Institute as well as collaborators from elsewhere to identify chemical probes and also leads a small projects team that specializes in many different molecular techniques.
Faloon joined the Broad Institute in 2009 after years of research experience in industry and academia. Faloon’s graduate work in the lab of Kyunghee Choi at Washington University involved characterizing a developmental precursor called a hemangioblast, which can develop into the cells that line the interior of blood vessels and lymphatic vessels (endothelial development) or into a variety of different kinds of blood cells and components. During his postdoctoral fellowship, Faloon studied endothelial development in zebrafish at Massachusetts General Hospital in the lab of Mark Fishman. Continuing his postdoctoral fellowship with Fishman at Novartis, Faloon also studied microglia, cells that reside in the brain, screening for compounds in zebrafish embryos that protect against neural injury.
Faloon received his Ph.D. in molecular and cellular biology from University of Maryland School of Medicine.
Faloon PW, et al. Basic fibroblast growth factor positively regulates hematopoietic development. Development. 2000 May;127(9):1931-41.
Chou DH, et al. Synthesis of a novel suppressor of beta-cell apoptosis via diversity-oriented synthesis. ACS Med Chem Lett. 2011 Sep 8;2(9):698-702.